{"id":1772,"date":"2022-10-11T13:31:00","date_gmt":"2022-10-11T11:31:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1772"},"modified":"2024-03-23T13:38:29","modified_gmt":"2024-03-23T12:38:29","slug":"9-liecivo-finerenon-kerendia-na-liecbu-pacientov-s-chronickou-chorobou-obliciek-spojenej-s-diabetes-mellitus-2-typu","status":"publish","type":"post","link":"https:\/\/niho.sk\/en\/9-liecivo-finerenon-kerendia-na-liecbu-pacientov-s-chronickou-chorobou-obliciek-spojenej-s-diabetes-mellitus-2-typu\/","title":{"rendered":"9: Lie\u010divo fineren\u00f3n (Kerendia) na lie\u010dbu pacientov s chronickou chorobou obli\u010diek spojenej s diabetes mellitus 2. typu"},"content":{"rendered":"<ol class=\"wp-block-list\">\n<li><strong>Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Chronick\u00e1 choroba obli\u010diek je nevylie\u010dite\u013en\u00e9 ochorenie, ktor\u00e9 v\u00fdznamne skracuje o\u010dak\u00e1van\u00e9 pre\u017e\u00edvanie pacientov. Je to jedn\u00fdm z celosvetovo najroz\u0161\u00edrenej\u0161\u00edch chronick\u00fdch ochoren\u00ed. Charakteristick\u00e1 je po\u0161koden\u00edm obli\u010diek a postupnou stratou ich funkcie, ktor\u00e1 kon\u010d\u00ed ich zlyhan\u00edm.&nbsp;<\/p>\n\n\n\n<p>Ochorenie negat\u00edvne ovplyv\u0148uje pacientov, ich pr\u00e1cu, financie a spolo\u010densk\u00fd \u017eivot. Pacienti kv\u00f4li tomu \u010dasto maj\u00fa depresiu, ktor\u00e1 ochorenie zhor\u0161uje.<\/p>\n\n\n\n<p>Na z\u00e1klade d\u00e1t N\u00e1rodn\u00e9ho centra zdravotn\u00edckych inform\u00e1ci\u00ed bolo v roku 2020 na Slovensku viac ako 46 tis\u00edc pacientov, ktor\u00ed trpia chronickou chorobou obli\u010diek a z\u00e1rove\u0148 cukrovkou 2. typu. Po zoh\u013eadnen\u00ed podmienok v tejto \u017eiadosti, pribli\u017ene 8,4 tis\u00edc z nich je vhodn\u00fdch pre lie\u010dbu fineren\u00f3nom.<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"2\">\n<li><strong>O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Kerendia (fineren\u00f3n) zmier\u0148uje z\u00e1pal a chr\u00e1ni tak tkaniv\u00e1 obli\u010diek a srdca. Kerendia 10 mg a 20 mg je dostupn\u00e1 vo forme tabliet, ktor\u00e9 sa u\u017e\u00edvaj\u00fa \u00fastnou formou raz denne. Pacient m\u00f4\u017ee lie\u010divo u\u017e\u00edva\u0165 s\u00e1m. D\u00e1vka, ktor\u00e1 sa m\u00e1 u\u017e\u00edva\u0165, z\u00e1vis\u00ed od funkcie obli\u010diek pacienta. Tablety sa m\u00f4\u017eu u\u017e\u00edva\u0165 s poh\u00e1rom vody a s jedlom alebo bez jedla.<\/p>\n\n\n\n<p>Kerendia bola registrovan\u00e1 v Eur\u00f3pskej liekovej agent\u00fare vo febru\u00e1ri roku 2022<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"3\">\n<li><strong>Ako sa na fineren\u00f3n pozeraj\u00fa odborn\u00edci?&nbsp;<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Odborn\u00edci, ktor\u00fdch NIHO oslovilo pre \u00fa\u010dely tohto hodnotenia uviedli, \u017ee fineren\u00f3n prin\u00e1\u0161a nov\u00fa mo\u017enos\u0165 lie\u010dby u pacientov s chronickou chorobou obli\u010diek spojenej s cukrovkou 2. typu &nbsp;a pozit\u00edvne ovplyv\u0148uje klinicky v\u00fdznamn\u00e9 obli\u010dkov\u00e9 a srdcovocievne ukazovatele.&nbsp;<\/p>\n\n\n\n<p>Jeden z odborn\u00edkov uviedol, \u017ee u pacientov s danou diagn\u00f3zou s\u00fa\u010dasn\u00e1 lie\u010dba nepon\u00faka lie\u010div\u00e1 ako fineren\u00f3n, ktor\u00e9 maj\u00fa protiz\u00e1palov\u00fd \u00fa\u010dinok. In\u00fd poznamenal, \u017ee najnov\u0161ie medzin\u00e1rodn\u00e9 odpor\u00fa\u010dania pre pacientov odpor\u00fa\u010daj\u00fa fineren\u00f3n.<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"4\">\n<li><strong>\u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Dr\u017eite\u013e registr\u00e1cie (Bayer AG) navrhuje hradi\u0165 lie\u010dbu fineren\u00f3nom (Kerendia) dospel\u00fdm pacientom s cukrovkou 2. typu a s diagn\u00f3zou chronickej choroby obli\u010diek &nbsp;3. a&nbsp;4. \u0161t\u00e1dia.<\/p>\n\n\n\n<p>V r\u00e1mci hodnotenej \u017eiadosti dr\u017eite\u013e registr\u00e1cie navrhuje \u00fahradu za 10 mg a 20 mg balenia Kerendia vo v\u00fd\u0161ke 2,504 eur.<\/p>\n\n\n\n<p class=\"has-custom-highlight-background-color has-background\">NIHO odpor\u00fa\u010da <strong>nevyhovie\u0165 <\/strong>\u017eiadosti o kategorizovanie lieku Kerendia, pokia\u013e:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><mark style=\"background-color:#f8ebb2\" class=\"has-inline-color\">ned\u00f4jde k \u00faprave podmienok hradenia na z\u00e1klade odpor\u00fa\u010dan\u00ed NIHO<\/mark><\/li>\n\n\n\n<li><mark style=\"background-color:#f8ebb2\" class=\"has-inline-color\">a z\u00e1rove\u0148 dr\u017eite\u013e registr\u00e1cie neposkytne z\u013eavu vo v\u00fd\u0161ke, ktor\u00fa navrhuje NIHO, aby:<\/mark><\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><mark style=\"background-color:#f8ebb2\" class=\"has-inline-color\">boli splnen\u00e9 krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti pod\u013ea \u00a77 z\u00e1kona 363\/2011 Z.z..<\/mark><\/li>\n\n\n\n<li><mark style=\"background-color:#f8ebb2\" class=\"has-inline-color\">bola zoh\u013eadnen\u00e1 ve\u013ek\u00e1 neistota d\u00e1t<\/mark><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>NIHO odpor\u00fa\u010da nevyhovie\u0165 \u017eiadosti o kategorizovanie lieku Kerendia, pokia\u013e&#8230;<\/p>","protected":false},"author":3,"featured_media":1774,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[28,29],"class_list":["post-1772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-finerenon","tag-kerendia"],"_links":{"self":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1772"}],"version-history":[{"count":0,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1772\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media\/1774"}],"wp:attachment":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}